Latest DecisionDx-UM Stories

2014-06-19 09:36:43

The JAMA Network Journals In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events. Uveal melanoma arises from melanocytes within the choroid layer of the eye. There...

2014-05-14 16:29:17

DecisionDx-Melanoma identifies patients with negative sentinel lymph node biopsies who are at high risk of metastasis FRIENDSWOOD, Texas, May 14, 2014 /PRNewswire/ -- Castle Biosciences Inc. announced today that abstracts reporting additional clinical validation data for two of its molecular tests -- one focused on melanoma and the other on esophageal adenocarcinoma -- will be presented at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30-June 3,...

2014-04-29 08:35:53

Presentation at the American Association for Thoracic Surgery 94th Annual Meeting TORONTO, April 29, 2014 /PRNewswire/ -- Castle Biosciences Inc. announced that data from two validation studies of its DecisionDx-Mesothelioma molecular test were presented at the American Association for Thoracic Surgery 94(th) Annual Meeting. According to the data, the test accurately predicted survival in metastatic pleural mesothelioma (MPM) patients based on the gene expression profile signature...

2014-03-22 20:20:22

Data presented at the Latest in Dermatology Research Symposia session of 72nd Annual Meeting of the American Academy of Dermatology DENVER, March 22, 2014 /PRNewswire/ -- Castle Biosciences Inc. today announced study results showing its gene expression profile (GEP) test (DecisionDx-Melanoma) can identify primary cutaneous (skin) melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy. The data are being presented at the Latest in...

2014-01-28 16:25:04

DURHAM, N.C. and ALISO VIEJO, Calif., Jan. 28, 2014 /PRNewswire/ -- bioMerieux, Inc. and Clarient, a GE Healthcare Company today announced that bioMerieux's molecular diagnostic test THxID®-BRAF has been added to the service offerings provided by Clarient. Clarient will use THxID® BRAF in order to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline's (GSK) Tafinlar® (dabrafenib) as well as...

Word of the Day
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.